Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 5039

1.

A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).

Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R; MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).

Clin Ther. 2002 Jan;24(1):126-38.

PMID:
11833827
3.
4.

An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.

Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, Amodeo C, Filho BL.

Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.

PMID:
18840367
5.

Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.

Chiou KR, Chen CH, Ding PY, Chen YT, Ting CT, Huang JL, Chiang AH, Liu CP, Tseng CJ, Chao CT, Chang MS.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 May;63(5):368-76.

PMID:
10862446
6.
7.

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL.

J Hum Hypertens. 2010 Feb;24(2):93-103. doi: 10.1038/jhh.2009.38. Epub 2009 May 21.

PMID:
19458624
8.

A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

Palma-Gamiz JL, Pêgo M, Marquez E, Pujol M, Olivan J, Alegría E, Sagastagoitia-Gorostiza JD, Gonzalez-Juanatey JR.

Clin Drug Investig. 2007;27(6):407-17.

PMID:
17506591
10.

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.

Malacco E, Santonastaso M, Varì NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study.

Clin Ther. 2004 Jun;26(6):855-65. Erratum in: Clin Ther. 2004 Jul;26(7):1185. Clin Ther. 2005 Jan;27(1):142.

PMID:
15262456
11.
12.

Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.

Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.

Clin Ther. 2004 Sep;26(9):1436-45.

PMID:
15531006
13.

A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.

Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R; COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators.

Am J Hypertens. 2005 Nov;18(11):1482-8.

PMID:
16280286
15.

Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.

de la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca Cusachs A, Sanz de Castro S, Pontes C, Delgadillo J.

J Hum Hypertens. 2004 Mar;18(3):215-22.

PMID:
14973517
16.

Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.

Coca A, Calvo C, Sobrino J, Gómez E, López-Paz JE, Sierra C, Bragulat E, de la Sierra A.

Clin Ther. 2003 Nov;25(11):2849-64.

PMID:
14693309
17.

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.

Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP.

Circulation. 2005 Mar 1;111(8):1012-8. Epub 2005 Feb 21.

18.

Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.

Lee H, Yang HM, Lee HY, Kim JJ, Choi DJ, Seung KB, Jeon ES, Ha JW, Rim SJ, Park JB, Shin JH, Oh BH.

Clin Ther. 2012 Jun;34(6):1273-89. doi: 10.1016/j.clinthera.2012.04.021. Epub 2012 May 17. Erratum in: Clin Ther. 2012 Sep;34(9):2020.

PMID:
22608107
19.
20.
Items per page

Supplemental Content

Write to the Help Desk